Li et al. (Protein Expr Purif. 2019; Int J Pharm. 2019) quantified the levels of long-acting IFN-γ by our ELISA Flex: Canine IFN-γ (HRP). In these studies, the authors aimed at improving quality and therapeutic effects of IFN-γ by creating the fusion proteins IFN-γ-CSA and CSA-IFN-γ, i.e. canine IFN-γ that was fused to canine serum albumin to create a cytokine drug for dogs. Here, Mabtech’s canine ELISAs were used for stability tests and pharmacokinetics.
IFN-γ has anti-viral, anti-tumor and immunomodulatory functions, but is rarely used in veterinarian medicine due to its short half-life and low bioavailability. IFN-γ-CSA, and even more so CSA-γ-gamma, showed potent anti-viral functionality, increased thermal stability and a significantly longer half-life than canine reIFN-γ. These results together with efficient in vivo antitumor activity emphasize the maximized therapeutic effects of IFN-γ fusion proteins.
Mabtech product used